Published Nov 19, 2026 | 7:00 AM ⚊ Updated Nov 19, 2026 | 7:00 AM
Antimicrobial Resistance. (iStock)
Synopsis: An ICMR report finds that several antibiotics commonly used to treat urinary, bloodstream and hospital-acquired infections are losing effectiveness against bacteria. Laboratory tests show high resistance to drugs including cefotaxime and ciprofloxacin, raising concerns about shrinking treatment options and the growing challenge of antimicrobial resistance in India.
Antibiotics that doctors commonly use to treat urinary infections, blood infections and other illnesses are becoming less effective against several bacteria found in hospitals across India, a new report by the Indian Council of Medical Research (ICMR) has found.
The report recorded particularly low effectiveness of several commonly used antibiotics against Escherichia coli (E. coli), a bacterium that commonly causes urinary infections, and Klebsiella pneumoniae, which can cause serious infections, including infections in the bloodstream and lungs.
Only 18.4% of E. coli samples tested by hospital laboratories responded to cefotaxime, an antibiotic used to treat several bacterial infections. The figure was 24.7% for ceftazidime and just 9% for ciprofloxacin.
In simple terms, fewer than two out of every 10 E. coli samples tested were sensitive to cefotaxime. The remaining samples did not respond to the drug in laboratory tests.
The findings are part of the ICMR’s Antimicrobial Resistance Surveillance and Research Network Annual Report 2025, which examined bacteria and fungi collected from hospitals between January and December 2025.
The report describes the resistance burden among major disease-causing bacteria as extensive, particularly among E. coli and Klebsiella. It warns that the findings have “important implications for empirical treatment, antimicrobial stewardship, infection prevention and control, and regional treatment guidelines”.
Antimicrobial resistance occurs when bacteria and other germs develop the ability to survive medicines that were previously able to kill them. This means an infection that could once be treated with a commonly prescribed antibiotic may become harder to control, forcing doctors to consider other medicines.
Also Read: In Andhra’s tribal belt, ICMR sanctions Rs 76 lakh to study meropenem resistance
E. coli was the most frequently identified bacterium in urine samples examined by ICMR. It accounted for 47.6% of the E. coli isolates found in urine samples in the tertiary-care hospital network.
The report found that several antibiotics commonly used against bacterial infections had low effectiveness against these E. coli samples.
Apart from cefotaxime and ceftazidime, only 9% of the samples were sensitive to ciprofloxacin, while 18.2% responded to levofloxacin. Both medicines belong to a group of antibiotics called fluoroquinolones.
These findings were not limited to patients admitted to hospitals. ICMR found low sensitivity even among samples collected from patients visiting outpatient departments (OPDs). This suggests that antibiotic resistance is also present among people who are not admitted to hospitals.
However, the report found that some medicines continued to work well against E. coli causing bladder infections. Fosfomycin was effective against 96.5% of the urine isolates tested, while nitrofurantoin was effective against 79.1%.
The report states that “fosfomycin demonstrated the highest overall susceptibility among the tested antibiotics”, followed by nitrofurantoin.
This does not mean that patients should choose these medicines themselves. The findings describe laboratory results, and the right antibiotic depends on the site and severity of infection, the patient’s condition and the sensitivity test.
The report also warns doctors against using certain antibiotics for kidney infections and urinary infections accompanied by fever, as resistance to several commonly used medicines is high.
The resistance problem was more pronounced in Klebsiella pneumoniae, another bacterium that can cause serious infections, particularly among hospitalised patients.
The report found that only 29.2% of Klebsiella samples were sensitive to piperacillin-tazobactam, an antibiotic combination used to treat serious bacterial infections.
Sensitivity to a group of antibiotics called third-generation cephalosporins was between 23% and 27%. Even carbapenems, a group of powerful antibiotics often used when other medicines do not work, were effective against only 35% to 40% of the samples.
Amikacin, another antibiotic, worked against 44.5% of the samples.
The report also says the findings indicate that “carbapenem resistance is becoming an increasingly important component of the overall resistance profile” of these bacteria.
Carbapenems are often considered important medicines for treating serious infections caused by bacteria that resist several other antibiotics. The declining effectiveness of these drugs leaves doctors with fewer treatment choices.
ICMR also examined the genetic mechanisms behind resistance. It found that some Klebsiella samples carried genes such as OXA-48 and NDM, which help bacteria survive carbapenem antibiotics.
The report says identifying the specific resistance mechanism is important because it can help doctors determine which newer medicines may work against an infection.
Also Read: From wells to illness: The hidden threat of antimicrobial resistance in tribal water access
The report found that bacteria collected from intensive care units (ICUs) were generally more resistant to antibiotics than those collected from outpatient departments and general wards.
This is particularly concerning because ICU patients are often critically ill, may have weakened immunity and may require invasive medical procedures such as ventilators and catheters.
Among Acinetobacter baumannii samples that were retested, 91.1% were resistant to carbapenems. This bacterium is a known cause of hospital-acquired infections and can be particularly difficult to treat.
The report also found that resistance among Klebsiella samples from ICU patients was high. Sensitivity to ertapenem, imipenem and meropenem was only 26.1%, 24.9% and 26.3%, respectively.
The ICMR assessment says ICU samples showed “substantially greater resistance across major antimicrobial classes” than samples from outpatients and general wards.
The report suggests that greater exposure to antibiotics, transmission of resistant bacteria within critical-care settings and other hospital-related factors may contribute to this pattern.
The report also highlights resistance among Staphylococcus aureus, a bacterium that can cause skin, wound and bloodstream infections.
More than half of the Staphylococcus aureus samples from tertiary-care hospitals were identified as methicillin-resistant Staphylococcus aureus (MRSA). The proportion was 56.8%.
MRSA refers to bacteria that can survive treatment with methicillin and several related antibiotics.
The findings were also concerning in secondary-care hospitals. Among hospitals with 500 beds or more, 86% of the Staphylococcus aureus samples were MRSA. The proportion was 54.1% in hospitals with 201 to 499 beds and 46.4% in hospitals with fewer than 200 beds.
However, the report found that vancomycin, teicoplanin and tigecycline remained effective against all MRSA samples tested in the secondary-care hospital network.
It also found that 20% of enterococci samples were resistant to vancomycin, an antibiotic used for serious infections. The resistance rate was higher in Enterococcus faecium than in Enterococcus faecalis.
The report also found a sharp difference in the response of typhoid bacteria to different antibiotics.
While typhoid samples remained highly sensitive to azithromycin (99.4%), ceftriaxone (96.6%) and trimethoprim-sulfamethoxazole (97.1%), only 2% responded to ciprofloxacin.
In other words, only about two out of every 100 typhoid samples tested were sensitive to ciprofloxacin.
The report advises against using carbapenems for routine typhoid treatment. It also highlights the need to select antibiotics based on laboratory testing rather than relying on medicines that may have worked in the past.
The 2025 report analysed 1,13,008 culture-positive bacterial and fungal isolates from 30 tertiary-care hospitals. It also included, for the first time, data from 34 secondary-care hospitals, including 12 district hospitals, which contributed another 20,529 isolates.
A culture test involves taking a sample, such as blood or urine, and growing the germs present in it in a laboratory. Doctors and laboratory teams can then test which antibiotics are able to stop the germs from growing.
The report’s percentages show how many tested samples were sensitive to a particular antibiotic. For example, if 20% of samples are sensitive to a drug, the remaining 80% did not show sensitivity in the laboratory test.
These figures do not mean that the same percentage of patients will fail treatment. The report records laboratory findings, not the number of people who recovered, developed complications or died.
ICMR has called for better antibiotic use, stronger infection-control measures in hospitals and treatment guided by local resistance patterns.
(Edited by Sumavarsha)